PMID- 7867008
OWN - NLM
STAT- MEDLINE
DCOM- 19950330
LR  - 20211203
IS  - 0008-5472 (Print)
IS  - 0008-5472 (Linking)
VI  - 55
IP  - 5
DP  - 1995 Mar 1
TI  - Detection of CDKN2 deletions in tumor cell lines and primary glioma by interphase 
      fluorescence in situ hybridization.
PG  - 984-8
AB  - Deletions of chromosomal band 9p21 have been detected in various tumor types 
      including melanoma, glioma, lung cancer, mesothelioma, and bladder cancer. 
      Recently, the CDKN2 gene (p16INK4A, MTS I, CDK41) has been proposed as a 
      candidate tumor suppressor gene because it is frequently deleted in cell lines 
      derived from multiple tumor types. We performed fluorescence in situ 
      hybridization (FISH) with interphase cells using yeast artificial chromosome 
      clones and a cosmid contig of the CDKN2 region. In 10 cell lines (4 glioma, 2 
      melanoma, 2 non-small cell lung cancer, 2 bladder cancer) with 9p alterations 
      detected by molecular or cytogenetic analysis, interphase FISH with the CDKN2 
      cosmid contig detected all 9p deletions previously identified by molecular 
      analysis. Using this probe, FISH analysis of primary glioblastoma tumors revealed 
      homozygous deletions of the CDKN2 region in 6 of 9 tumors (67%) whereas a yeast 
      artificial chromosome probe containing the interferon type I (IFN) gene cluster 
      was deleted in only 4 cases (44%). Thus, it is likely that the CDKN2 region is 
      the target of 9p deletions in gliomas. Interphase FISH will play an important 
      role in defining the clinical significance of 9p deletions in primary tumors 
      because it is especially applicable to clinical samples which may be contaminated 
      by normal cells.
FAU - Dreyling, M H
AU  - Dreyling MH
AD  - Department of Medicine, University of Chicago, Illinois 60637.
FAU - Bohlander, S K
AU  - Bohlander SK
FAU - Adeyanju, M O
AU  - Adeyanju MO
FAU - Olopade, O I
AU  - Olopade OI
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Cancer Res
JT  - Cancer research
JID - 2984705R
RN  - 0 (Proto-Oncogene Proteins)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
RN  - EC 2.7.11.22 (CDK4 protein, human)
RN  - EC 2.7.11.22 (Cyclin-Dependent Kinase 4)
RN  - EC 2.7.11.22 (Cyclin-Dependent Kinases)
SB  - IM
GS  - CDK41
GS  - CDKN2
GS  - IFN
GS  - IFN<up>3</up>
GS  - MTS 1
GS  - p16<up>INK4A</up>
MH  - Brain Neoplasms/*genetics
MH  - Carcinoma, Non-Small-Cell Lung/genetics
MH  - *Chromosomes, Human, Pair 9
MH  - Cyclin-Dependent Kinase 4
MH  - *Cyclin-Dependent Kinases
MH  - *Gene Deletion
MH  - *Genes, Tumor Suppressor
MH  - Glioma/*genetics
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Interphase/physiology
MH  - Lung Neoplasms/genetics
MH  - Melanoma/genetics
MH  - Neoplasms/*genetics
MH  - Protein Serine-Threonine Kinases/*genetics
MH  - *Proto-Oncogene Proteins
MH  - Tumor Cells, Cultured
MH  - Urinary Bladder Neoplasms/genetics
EDAT- 1995/03/01 00:00
MHDA- 1995/03/01 00:01
CRDT- 1995/03/01 00:00
PHST- 1995/03/01 00:00 [pubmed]
PHST- 1995/03/01 00:01 [medline]
PHST- 1995/03/01 00:00 [entrez]
PST - ppublish
SO  - Cancer Res. 1995 Mar 1;55(5):984-8.